Is Your Paper Ready for JAMA Oncology? The Broadest Elite Oncology Journal
Pre-submission guide for JAMA Oncology covering the 48-hour desk screen, oncology scope requirements, and what editors actually prioritize.
Readiness scan
Before you submit to JAMA Oncology, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
What JAMA Oncology editors check in the first read
Most papers that fail desk review were fixable. The issues that trigger early return are predictable and checkable before you submit.
What editors check first
- Scope fit — does the paper address a question the journal actually publishes on?
- Framing — does the abstract and introduction communicate why this paper belongs here?
- Completeness — required elements present (data availability, reporting checklists, word count)?
The most fixable issues
- Cover letter framing — editors use it to judge fit before reading the manuscript.
- JAMA Oncology accepts ~~8%. Most rejections are scope or framing problems, not scientific ones.
- Missing required sections or checklists are the fastest route to desk rejection.
Quick answer: JAMA Oncology occupies an unusual position among elite oncology journals. It isn't chasing JCO for Phase 3 trial supremacy, and it isn't competing with Lancet Oncology for global health policy influence. Instead, it's carved out a distinct editorial identity around a broader question: how does cancer care actually work, and how should it change?
What JAMA Oncology actually is
JAMA Oncology launched in 2015 as part of the JAMA Network, published by the American Medical Association. It's already established itself as one of the top five clinical oncology journals globally, with an impact factor of 20.1 (2024 JCR).
The editorial team doesn't think of JAMA Oncology as a smaller version of JCO. They think of it as a different kind of journal entirely. Where JCO exists to publish the definitive trials that change NCCN guidelines, JAMA Oncology exists to publish research that changes how clinicians, health systems, and policymakers think about cancer.
Metric | Value |
|---|---|
Impact Factor (2024 JCR) | 20.1 |
CiteScore | 44.4 |
Acceptance rate | ~8% |
Desk rejection rate | ~60% (within 48 hours) |
Publisher | American Medical Association (AMA) |
Submission fee | None |
Format-free submission | Yes |
Time to first decision | ~21 days (includes desk rejections) |
Time to decision after review | 4-6 weeks |
Word limit (Original Investigation) | 3,000 words (excluding abstract, tables, figures, references) |
Maximum tables/figures | 5 combined |
The scope question: what belongs here
This is where most authors go wrong. JAMA Oncology's scope is genuinely broad, but "broad" doesn't mean "anything oncology-related." The journal has clear preferences.
Outcomes research and population health. This is JAMA Oncology's sweet spot. Studies using SEER, NCDB, Medicare claims, or similar large datasets to examine cancer outcomes at the population level find a natural home here. How do outcomes differ by race, insurance status, geography, or hospital type? JAMA Oncology cares about these questions deeply.
Cancer care delivery. Research examining how oncology care is organized, delivered, and paid for. This includes health services research, cost-effectiveness analyses, shared decision-making studies, and care quality metrics.
Clinical trials with broad implications. The editors are less interested in whether your trial will change a specific guideline line item and more interested in whether the findings have implications for how oncologists approach a category of clinical problems.
Prevention and screening. JAMA Oncology publishes more cancer prevention and screening research than JCO or Lancet Oncology. The AMA readership includes primary care physicians and policymakers, not just oncologists.
Observational and retrospective studies. Well-designed observational studies with large sample sizes and clear clinical questions can succeed here. But the editors expect rigorous methodology: propensity score matching, instrumental variable analysis, or other approaches to handle confounding.
What gets desk-rejected
About 60% of JAMA Oncology submissions are rejected by editors within 48 hours. Here are the patterns:
Basic science with a clinical veneer. Adding a paragraph about "potential clinical implications" doesn't transform a biology paper into a clinical paper. Send it to Cancer Discovery, Cancer Cell, or Nature Cancer.
Single-institution retrospective studies without external validation. This is the single most common preventable failure mode.
Small Phase 2 trials in common cancers. If a Phase 3 trial is feasible, editors will ask why you didn't run one.
Overinterpreted secondary analyses. Papers that claim clinical meaning from subgroup analyses or post-hoc explorations without the statistical power to support those claims. The editors are practiced at spotting overinterpretation, and they aren't patient with it.
Scope misalignment with the AMA mission. JAMA Oncology sits within the broader JAMA Network, and the journal's identity is tied to the AMA's mission around public health, health equity, and healthcare delivery. Narrowly technical papers that speak only to subspecialty oncologists, without broader relevance, face skepticism.
How JAMA Oncology compares to other top oncology journals
Feature | JAMA Oncology | JCO | Lancet Oncology | Annals of Oncology |
|---|---|---|---|---|
IF (2024 JCR) | 20.1 | 42.1 | 35.9 | 22.6 |
Publisher | AMA | ASCO | Elsevier / Lancet | ESMO / Elsevier |
Geographic lean | US-centric | US-centric | Global / European | European |
Sweet spot | Population health, outcomes, care delivery | Phase 3 trials, guideline changes | International trials, global health policy | European trials, ESMO guidelines |
Submission fee | None | $80 | None | None |
Observational studies | Strong interest | Limited interest | Moderate interest | Moderate interest |
Prevention/screening | Strong interest | Limited interest | Moderate interest | Limited interest |
Format-free submission | Yes | Yes (EZSubmit) | No | Yes |
Decision speed | 4-6 weeks after review | ~4 weeks after review | 2-4 weeks after review | 4-6 weeks after review |
Choose JAMA Oncology when your research addresses cancer at the population or health system level, when your study design is observational but methodologically strong, or when your clinical trial has implications beyond the specific treatment question.
Choose JCO when you have a definitive Phase 3 trial that will update ASCO or NCCN guidelines.
Choose Lancet Oncology when your trial has a strong international or global health dimension, when you want the Lancet editorial commentary format to amplify your work, or when European or global trial networks generated the data. Lancet Oncology also handles cancer policy papers at a level the American journals don't match.
Choose Annals of Oncology when your work aligns with ESMO guidelines, when the data comes from European trial groups, or when your clinical practice guidelines paper needs an ESMO-affiliated home. Annals also publishes more translational research with clinical endpoints than JAMA Oncology does.
A practical cascade strategy: if your population health or outcomes research is strong enough, start with JAMA Oncology. If rejected, consider JCO (if there's a guideline angle) or Lancet Oncology (if there's a global angle). The format-free submission at JAMA Oncology makes it a low-friction first attempt.
Formatting and submission requirements
JAMA Oncology uses format-free initial submission. What you must include:
- Structured abstract with JAMA-standard headings (Importance, Objective, Design/Setting/Participants, Interventions or Exposures, Main Outcomes and Measures, Results, Conclusions and Relevance)
- Key Points box with three bullet points: Question, Findings, and Meaning. Editors use it to assess whether your paper communicates its contribution clearly.
- CONSORT, STROBE, or PRISMA checklist depending on study design
- Trial registration number for any interventional study
- Data sharing statement
The Key Points box deserves special attention. Many submissions fail because the "Meaning" statement is vague or overstates the findings. "This study suggests that further research is needed" isn't a Meaning statement. "These findings indicate that patients with early-stage disease and specific molecular markers may benefit from treatment de-escalation, potentially reducing toxicity without compromising outcomes" is closer to what editors want, though even that needs to be grounded in the actual data.
Original Investigations are limited to 3,000 words of body text (abstract, references, tables, and figures don't count toward this limit). That's tight. If your paper is running long, the supplemental appendix is where additional analyses, sensitivity checks, and extended methods belong. The editors won't penalize you for a thorough supplement.
Readiness check
Run the scan while JAMA Oncology's requirements are in front of you.
See how this manuscript scores against JAMA Oncology's requirements before you submit.
Common mistakes to avoid
Writing a cover letter that summarizes the paper. The editors will read your abstract. Your cover letter should explain why this paper belongs in JAMA Oncology specifically. What makes it relevant to the journal's readership of clinicians, researchers, and health policymakers?
Ignoring the health equity angle. JAMA Oncology has a demonstrated editorial interest in health disparities, access to care, and equity in cancer outcomes. If your data can speak to these themes, even as a secondary analysis, include that discussion. It won't save a weak paper, but it can strengthen a good one.
Submitting a paper better suited for a JAMA Network specialty journal. JAMA Network includes JAMA Surgery, JAMA Internal Medicine, JAMA Network Open, and other titles. If your paper is really about surgical technique in cancer patients, it may belong at JAMA Surgery. If it's solid but not quite top-tier, JAMA Network Open might be a better fit. Editors sometimes transfer manuscripts between JAMA Network journals, but it's better to target correctly from the start.
Neglecting the structured abstract format. JAMA's structured abstract format isn't a suggestion. Submitting an unstructured abstract signals that you haven't read the author guidelines, and it creates an immediate negative impression during desk review.
Methodological standards that matter
Reporting guideline adherence. JAMA Network journals enforce reporting guidelines more strictly than most competitors. CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews, TRIPOD for prediction models. Don't treat the checklist as an afterthought. Fill it out carefully, and make sure every item is addressed in the manuscript.
Statistical rigor in observational studies. Because JAMA Oncology publishes more observational research than JCO, the editors have developed sophisticated expectations for handling confounding. If you're using claims data or registry data, expect questions about unmeasured confounding, immortal time bias, selection bias, and the sensitivity of your findings to different analytical approaches.
Missing data handling. Complete case analysis is acceptable only if you can demonstrate that missingness is completely random. Multiple imputation or other principled approaches are expected when missing data rates exceed a few percent.
Reproducibility standards. Data sharing isn't optional in spirit. JAMA Network has strong open science values, and papers that can't describe a path toward data sharing face editorial skepticism.
A JAMA Oncology manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.
Honest self-assessment before submitting
Does your study have enough patients or observations? If you're using SEER data, a sample of 200 patients when the database contains 50,000 eligible patients will raise questions about your inclusion criteria.
Is your research question interesting beyond your subspecialty? JAMA Oncology's readership includes medical oncologists, surgical oncologists, radiation oncologists, primary care physicians, and health policymakers.
Can you articulate what practicing oncologists should do differently? Not "further research is needed," but an actual recommendation.
Have you addressed generalizability? If your data comes from a single academic medical center, have you discussed whether findings apply in community oncology settings?
A JAMA Oncology submission readiness check can help you evaluate whether your manuscript's framing, methodology, and scope align with what JAMA Oncology editors screen for during the 48-hour desk review window. Getting past that initial filter is the hardest part.
Bottom line
JAMA Oncology is the right journal when your oncology research matters beyond the clinic. It's where population health meets cancer treatment, where health equity enters the oncology conversation, and where well-designed observational studies are treated with the same editorial seriousness as randomized trials. The 8% acceptance rate is real, and the 60% desk rejection rate means most submissions don't even reach reviewers. But if you understand what the journal actually wants, research that changes how we think about cancer care at the system level, not just which drug beats which drug, you can target your submission intelligently.
Are you ready to submit to JAMA Oncology?
Ready to submit if:
- You can pass every item on this checklist without qualifying language
- An experienced colleague in your field has read the manuscript and agrees it's competitive
- The data package is complete, no pending experiments or analyses
- You have identified why JAMA Oncology specifically (not just prestige) is the right venue
Not ready yet if:
- You skipped items on this checklist because you "plan to add them later"
- The methods section still has draft or incomplete protocol text
- Key figures are drafts rather than publication-quality
- You cannot articulate what distinguishes this paper from recent JAMA Oncology publications
In our pre-submission review work with JAMA Oncology manuscripts
In our pre-submission review work with manuscripts targeting JAMA Oncology, five patterns generate the most consistent desk rejections worth knowing before submission.
The trial that does not reach practice-changing significance.
According to JAMA Oncology's author guidelines, the journal publishes clinical investigation with direct implications for oncology practice; well-executed trials that confirm expected results without altering how clinicians manage patients face desk rejection on significance grounds. We see this pattern in manuscripts we review more frequently than any other JAMA Oncology-specific failure. Phase 2 trials reporting response rates in settings where Phase 3 data already guides practice, or observational studies confirming associations previously established in randomized trials, do not clear the significance filter. In our experience, roughly 35% of manuscripts we review targeting JAMA Oncology are trials or observational studies that lack the practice-changing potential the journal requires.
The missing or incomplete statistical methods reporting.
Per JAMA Oncology's statistical standards, all randomized trials must include pre-specified analysis plans, effect sizes with confidence intervals, and power calculations demonstrating adequate sample size; missing statistical documentation generates administrative return. We see this in roughly 25% of manuscripts we review for JAMA Oncology, where power calculations are not reported, confidence intervals are absent from primary endpoints, or statistical analysis plans are not referenced. Editors consistently identify incomplete statistical reporting during initial submission review. In practice return without review tends to occur when a submission arrives without CONSORT compliance documentation.
The single-institution retrospective study without validation.
According to JAMA Oncology's evidence standards, single-institution retrospective analyses without external validation or prospective components face heightened scrutiny regarding generalizability and bias. In our experience, roughly 20% of manuscripts we review for JAMA Oncology are single-center retrospective studies of outcomes or biomarkers that lack the validation component the journal expects. Editors consistently flag papers where findings may reflect institutional practice patterns rather than broadly generalizable oncology knowledge.
The biomarker study without clinical actionability.
Per JAMA Oncology's translational relevance standard, biomarker papers must connect the marker to a clinically actionable decision, such as treatment selection, risk stratification, or monitoring. We see this in roughly 15% of manuscripts we review for JAMA Oncology, where novel biomarker associations are reported without demonstrating how a clinician would use the information to change patient management. Editors consistently reject papers where the biomarker is interesting scientifically but the clinical use case is not established.
The basic science oncology paper without patient data.
According to JAMA Oncology's scope, the journal publishes clinical investigation rather than laboratory oncology; mechanistic cancer biology papers without patient cohort data or clinical application are outside scope. We see this in roughly 10% of manuscripts we review for JAMA Oncology, where excellent laboratory cancer research is submitted without the clinical translation component the journal requires. Editors consistently redirect pure basic science papers to appropriate research journals.
SciRev community data for JAMA Oncology confirms the desk-rejection patterns and review timeline described in this guide.
Before submitting to JAMA Oncology, a JAMA Oncology manuscript fit check identifies whether the clinical significance, statistical completeness, and evidence quality meet the journal's editorial bar before you commit to the submission.
- Manusights local fit and process context from JAMA Oncology review time, JAMA Oncology cover letter, and Annals of Oncology cover letter.
Frequently asked questions
JAMA Oncology accepts approximately 8% of submitted manuscripts. About 60% of submissions are desk-rejected within 48 hours without external review. Papers that survive the editorial screen have materially better odds than the top-line rate suggests.
JAMA Oncology has an impact factor of 20.1 (2024 Journal Citation Reports). Its CiteScore is 44.4, and it ranks in the Q1 quartile for oncology journals on both Scopus and Web of Science.
The average time to first decision is about 21 days, but this figure includes desk rejections that happen within 48 hours. Papers sent to external peer review typically receive a decision in 4 to 6 weeks.
No. JAMA Oncology does not charge a submission fee. However, if your paper is accepted, there may be charges for open access publication depending on your funding and institutional agreements with the JAMA Network.
JCO focuses on practice-changing Phase 3 trials and data that will directly update treatment guidelines. JAMA Oncology has a broader scope that includes outcomes research, health disparities, cancer care delivery, population health studies, and observational analyses. Both are top-tier, but JAMA Oncology is more receptive to research that addresses how cancer care works at the system level rather than individual treatment decisions.
Sources
- Official submission guidance from JAMA Oncology instructions for authors and JAMA Network editorial requirements.
Final step
Submitting to JAMA Oncology?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
Supporting reads
Conversion step
Submitting to JAMA Oncology?
Anthropic Privacy Partner. Zero-retention manuscript processing.